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abstract
PURPOSE CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally
advanced or metastatic urothelial carcinoma (mUC) treated with nivolumab 3 mg/kg monotherapy every
2 weeks (NIVO3), nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by
nivolumab monotherapy 3 mg/kg every 2 weeks (NIVO3+IPI1), or nivolumab 1 mg/kg plus ipilimumab
3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks
(NIVO1+IPI3). We report on the expanded NIVO1+IPI3 cohort and extended follow-up for the NIVO3 and
NIVO3+IPI1 cohorts.
METHODS Patients with platinum-pretreated mUC were enrolled in this phase I/II multicenter study to receive
NIVO3, NIVO3+IPI1, or NIVO1+IPI3 until disease progression or unacceptable toxicity. Primary end point was
investigator-assessed objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) version
1.1, including duration of response.
RESULTS Seventy-eight patients were treated with NIVO3 (minimum follow-up, 37.7 months), 104 with NIVO3+IPI1
(minimum follow-up, 38.8 months), and 92 with NIVO1+IPI3 (minimum follow-up, 7.9 months). Objective response
ratewas 25.6%, 26.9%, and 38.0% in theNIVO3,NIVO3+IPI1, andNIVO1+IPI3 arms, respectively.Median duration
of response was more than 22 months in all arms. Grade 3 or 4 treatment-related adverse events occurred in 21
(26.9%), 32 (30.8%), and 36 (39.1%) patients treated with NIVO3, NIVO3+IPI1, and NIVO1+IPI3, respectively.
Grade 5 treatment-related pneumonitis occurred in one patient each in the NIVO3 and NIVO3+IPI1 arms.
CONCLUSIONWith longer follow-up, NIVO3 demonstrated sustained antitumor activity alone and in combination
with ipilimumab. NIVO1+IPI3 provided the greatest antitumor activity of all regimens, with a manageable safety
profile. This result not only supports additional study of NIVO1+IPI3 in mUC, but demonstrates the potential
benefit of immunotherapy combinations in this disease.
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INTRODUCTION
Immunotherapies have become a standard of care
for previously treated metastatic urothelial carci-
noma (mUC).1 Programmed death 1 (PD-1) immune
checkpoint inhibitor nivolumab is approved as mon-
otherapy for patients with locally advanced or mUC
who experienced progression after platinum-containing
chemotherapy.2 In the single-arm, phase II CheckMate
275 trial, nivolumab demonstrated a clinically mean-
ingful objective response rate (ORR) of 20.4%, median
overall survival (OS) of 8.6 months, 1-year OS rate of
40%, and a tolerable safety profile with median follow-
up of 24.5 months.3
Other immunotherapy monotherapies for platinum-
resistant mUC include pembrolizumab, atezolizu-
mab, durvalumab, and avelumab,1 with reported
median OS ranging from 6.5 months to 18.2 months
and ORR ranging from 13.4% to 21.1% in pro-
grammed death ligand 1 (PD-L1) unselected
patients.4-8 Of phase III trials reported in this set-
ting, OS benefit was observed in one study of
pembrolizumab versus investigator’s choice of
chemotherapy.4,9 The clear benefits observed with
immune checkpoint monotherapies demand in-
vestigation of how outcomes might be improved with
combination therapies.
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Combination treatments are under investigation in
mUC to optimize the antitumor effects of immune check-
point inhibition.10 Combined inhibition of PD-1 and cyto-
toxic T-lymphocyte antigen-4 with nivolumab and
ipilimumab has demonstrated benefit in several tumor
types.11-14 This treatment is approved for the treatment of
patients with microsatellite instability–high or mismatch
repair–deficient metastatic colorectal cancers that have
progressed after combination therapy with fluoropyr-
imidine, oxaliplatin, and irinotecan, as well as intermediate-
and poor-risk patients with previously untreated advanced
renal cell carcinoma (RCC) and in patients with previously
untreated metastatic melanoma.2,15
CheckMate 032 evaluates several advanced tumor types.16
Patients in the locally advanced or metastatic platinum-
pretreated urothelial carcinoma (UC) cohort received
nivolumab monotherapy (nivolumab 3 mg/kg every
2 weeks [NIVO3]) or one of two nivolumab plus ipili-
mumab combination regimens (nivolumab 3 mg/kg +
ipilimumab 1 mg/kg [NIVO3+IPI1] every 3 weeks for four
doses followed by nivolumab monotherapy mainte-
nance or nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
[NIVO1+IPI3] every 3 weeks for four doses followed by
nivolumab monotherapy maintenance). Interim results
for patients with mUC who received NIVO3 (minimum
follow-up, 9 months),16 outcomes with NIVO3 after
longer follow-up (minimum follow-up, 24 months),17 and
initial results for the combination treatment arms
(minimum follow-up, 3.9 months [NIVO1+IPI3] and
14.5 months [NIVO3+IPI1])18 have been reported. Here, we
report the results from CheckMate 032 with extended follow-
up data from all three treatment arms (minimum follow-up,
37.7 months, 38.8 months, and 7.9 months in the NIVO3,
NIVO3+IPI1, and NIVO1+IPI3 arms, respectively).
METHODS
Study Design and Participants
CheckMate 032 is a multicenter, open-label, multiarm,
phase I/II trial.16 Patients in the UC cohort were enrolled at
38 sites in eight countries. Eligible patients were age
18 years or older with histologically or cytologically con-
firmed UC of the renal pelvis, ureter, bladder, or urethra;
had experienced disease progression after receiving one
or more previous platinum-based chemotherapy for
metastatic or locally advanced unresectable disease; had
experienced recurrence within 1 year of completing
platinum-based neoadjuvant or adjuvant treatment; or had
refused standard treatment with chemotherapy for meta-
static or locally advanced unresectable disease. Patients
had Eastern Cooperative Oncology Group performance
status of 0 or 1 and measurable disease per Response
Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Key exclusion criteria were active brain metastases, history
of or active autoimmune disease, conditions that required
systemic corticosteroids (. 10 mg per day prednisone
equivalent), and any prior treatment with experimental
antitumor vaccines or a modulator of T-cell function or
immune checkpoint pathway.
Patients in the UC cohort were assigned to treatment with
either NIVO3, NIVO3+IPI1, or NIVO1+IPI3. Patients were
randomly assigned among treatment arms that were open
at the time of enrollment. The NIVO1+IPI3 arm was later
expanded via protocol amendment. Additional patients
were enrolled in this arm after enrollment was closed for the
NIVO3 and NIVO3+IPI1 arms.
The protocol was approved by the institutional review board
or independent ethics committee at each site and
conducted in accordance with Good Clinical Practice
guidelines according to International Conference on
Harmonisation guidelines. All patients provided written
informed consent to participate, per the Declaration of
Helsinki.
Procedures
Patients received treatment with NIVO3, NIVO3+IPI1, or
NIVO1+IPI3 until disease progression or unacceptable
toxicity. Dose reductions were not permitted. Treatment
beyond disease progression was permitted if a patient
tolerated study treatment and experienced investigator-
assessed clinical benefit. Patients in the NIVO3 arm
could switch to NIVO3+IPI1 or NIVO1+IPI3 combination
treatment after disease progression if they met protocol-
specified criteria. Patients who achieved an initial objective
response that lasted 3 or more months could hold treat-
ment. In the case of subsequent progression, patients
could undergo re-exposure with the combination treatment
if they achieved an initial objective response or stable
disease that lasted 3 or more months, had subsequent
documented disease progression, and met other pre-
defined criteria.
Tumor assessments were performed using computed to-
mography or magnetic resonance imaging at baseline,
every 6 weeks (61 week) from the first dose for the first
24 weeks, then every 12 weeks (61 week) thereafter.
Assessments were completed by the investigator, per
RECIST v1.1. Safety assessments were completed con-
tinuously. Adverse events (AEs) were graded according to
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0.
Tumor PD-L1 expression was assessed retrospectively from
mandatory tumor biopsies using the Dako PD-L1 immu-
nohistochemical 28-8 pharmDx kit (Dako, Santa Clara, CA).
Outcomes
Primary end point was ORR, per the investigator, which
required confirmation per RECIST v1.1. ORR was further
characterized by the duration of response (DOR). ORR was
also evaluated by blinded independent central review
(BICR) in the NIVO3 and NIVO1+IPI3 arms to evaluate
efficacy in the NIVO1+IPI3 expansion cohort.
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Secondary end points included progression-free survival
(PFS), OS, and safety and tolerability. Treatment-related
select AE categories were those with a potential in-
flammatory mechanism that required more frequent
monitoring or unique intervention, such as immuno-
suppressants or endocrine replacement therapy. Effi-
cacy by tumor PD-L1 expression was an exploratory
end point.
Statistical Analysis
The study was conducted with a one-stage design with
a sample size of 60 to 100 patients in the NIVO3 and
NIVO3+IPI1 arms for 90% to 97% power to reject the null
hypothesis of 10% response rate if the true response rate
was 25% with a two-sided type I error rate of 5%. For the
NIVO1+IPI3 arm, initial enrollment of 26 patients was
planned, of which six patients were enrolled for safety
evaluation while the NIVO3 arm was open, and 20 patients
after the other two arms completed enrollment; there were
26 patients in the NIVO1+IPI3 arm at the initial disclosure
of results with minimum follow-up of 3.9 months.18 The
protocol was amended in October 2016 to expand the
NIVO1+IPI3 arm to enroll 92 patients—an additional
66 patients. On the basis of a 19.6% ORR for nivolumab
monotherapy,7 this would provide 93% power to reject the
null hypothesis of a 19.6% ORR if the true ORR was 35%
with a two-sided type I error rate of 5%. We analyzed ORR
using the Clopper-Pearson method.19 DOR was analyzed
using the Kaplan-Meier methodology, and median values
along with two-sided 95% CI were calculated using the
Brookmeyer and Crowley method.20 PFS and OS were
summarized descriptively using the Kaplan-Meier method.
Safety outcomes were tabulated using the worst grade
according to National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0, by system organ class
and preferred term. All analyses were performed in all treated
patients from each arm. Analyses reported here were
completed when the primary end point of ORR could be
evaluated in all treated patients.
RESULTS
Patients in the CheckMate 032 UC cohort were enrolled
from June 5, 2014, to September 28, 2017. There were 78,
104, and 92 treated patients in the NIVO3, NIVO3+IPI1,
and NIVO1+IPI3 arms, respectively. Patients were ran-
domly assigned between the NIVO3 and NIVO3+IPI1 arms,
which were enrolling at the same time. In contrast, 86 of 92
treated patients in the NIVO1+IPI3 arm were enrolled after
the other two arms completed enrollment, thus leading to
the differing lengths of follow-up. Baseline demographic
and clinical characteristics were generally similar across
treatment arms; however, more patients in the NIVO3+IPI1
and NIVO1+IPI3 arms had two or more Bellmunt risk
factors and liver metastasis compared with the NIVO3 arm
(Table 1). Two patients (1.9%) in the NIVO3+IPI1 arm
and three patients (3.3%) in the NIVO1+IPI3 arm did not
receive prior chemotherapy. More than 60% of patients
in each arm received two or more prior treatment regimens.
Patients received a median of 8.5 nivolumab doses
(range, one to 93 doses) in the NIVO3 arm, 4.0 nivolumab
doses (range, one to 87 doses), and 4.0 ipilimumab doses
(range one to eight doses) in the NIVO3+IPI1 arm, and
4.0 nivolumab doses (range, one to 102 doses) and
3.0 ipilimumab doses (range, one to eight doses) in the
NIVO1+IPI3 arm. In the NIVO3+IPI1 and NIVO1+IPI3
arms, 53 (50.9%) and 44 (47.8%) patients, respectively,
received all four doses of the combination. Median du-
ration of therapy was 3.5 months (95% CI, 2.3 to
5.1 months), 2.1 months (95% CI, 1.4 to 2.3 months),
and 3.2 months (95% CI, 2.1 to 6.9 months) in the
NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms, respec-
tively. At the data cutoff, seven (9.0%), eight (7.7%),
and 22 patients (23.9%) were continuing treatment in the
NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms, respectively.
Disease progression was the most common reason for dis-
continuation (Fig 1). In the NIVO3, NIVO3+IPI1, and
NIVO1+IPI3 arms, 26 (33.3%), 28 (26.9%), and 16 pa-
tients (17.4%), respectively, received subsequent sys-
temic therapy.
Confirmed ORR, per investigator, was 25.6% (95% CI,
16.4% to 36.8%) in the NIVO3 arm, 26.9% (95% CI,
18.7% to 36.5%) in the NIVO3+IPI1 arm, and 38.0%
(95% CI, 28.1% to 48.8%) in the NIVO1+IPI3 arm
(Table 2 and Appendix Fig A1A, online only). In the
NIVO1+IPI3 arm, ORR was 23.8% (95% CI, 12.1% to
39.5%) in patients with tumor PD-L1 less than 1% at
baseline and 58.1% (95% CI, 39.1% to 75.5%) in patients
with tumor PD-L1 expression of 1% or greater at baseline
(Appendix Fig A1A and Appendix Table A1, online only).
ORR, per BICR, was concordant with the per-investigator
assessment in the NIVO3 and NIVO1+IPI3 arms (Table 2
and Appendix Fig A1B). ORR by tumor PD-L1 expression
level, per BICR, was also concordant with investigator
review in the NIVO3 and NIVO1+IPI3 arms (Appendix
Fig A1B).
Median time to response, per investigator, was 2.0
months (range, 1.0 to 8.3 months), 1.4 months (range,
1.1 to 11.1 months), and 1.4 months (range, 1.1 to 5.1
months) in the NIVO3, NIVO3+IPI1, and NIVO1+IPI3
arms, respectively. Median DOR was 30.5 months (95%
CI, 8.3 months to not estimable [NE]) in the NIVO3 arm,
22.3 months (95% CI, 12.8 months to NE) in the
NIVO3+IPI1 arm, and 22.9 months (95% CI, 9.8 months
to NE) in the NIVO1+IPI3 arm. Median DOR in each arm
was similar regardless of baseline tumor PD-L1 expres-
sion (Appendix Table A1). Median tumor change from
baseline was +1.9%, 0%, and 230.0% in the NIVO3,
NIVO3+IPI1, and NIVO1+IPI3 arms, respectively (Fig 2).
Several patients in each arm demonstrated prolonged
reduction in target lesions from baseline (Appendix Fig A2,
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online only) and durable responses (Appendix Fig A3,
online only).
Median PFS was 2.8 months (95% CI, 1.5 to 5.3 months),
2.6 months (95% CI, 1.4 to 3.9 months), and 4.9 months
(95%CI, 2.7 to 6.6months) in the NIVO3, NIVO3+IPI1, and
NIVO1+IPI3 arms (Fig 3). Six-month PFS rates in the
NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms were 36.3%,
32.3%, and 41.7%, respectively. Twelve-month PFS rates
in the NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms were
17.9%, 22.6%, and 25.9%, respectively. In patients with
baseline PD-L1 expression less than 1%, median PFS was
2.8 months (95% CI, 1.4 to 5.9 months), 2.7 months (95%
CI, 1.4 to 3.9 months), and 4.3 months (95% CI, 1.5 to
6.4 months) in the NIVO3, NIVO3+IPI1, and NIVO1+IPI3
arms, respectively. In patients with PD-L1 expression of 1%
or greater, median PFS was 2.7 months (95% CI, 1.2 to
10.8 months), 3.4 months (95% CI, 1.4 to 11.0 months),
and 6.6 months (95% CI, 3.8 to 27.6 months) in the
NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms (Appendix
Fig A4, online only). Median OS was 9.9 months (95% CI,
7.3 to 21.1 months) in the NIVO3 arm, 7.4 months (95%
CI, 5.6 to 11.0 months) in the NIVO3+IPI1 arm, and
15.3 months (95% CI, 10.1 to 27.6 months) in the
NIVO1+IPI3 arm (Fig 4). Twelve-month OS rates were
47.3%, 38.3%, and 56.9% in the NIVO3, NIVO3+IPI1,
and NIVO1+IPI3 arms, respectively. In patients with PD-
L1 expression less than 1%, median OS was 10.4 months
(95% CI, 6.5 to 26.0 months), 7.4 months (95% CI, 5.0 to
10.6 months), and 14.9 months (95% CI, 5.6
to 27.6 months) in the NIVO3, NIVO3+IPI1, and
NIVO1+IPI3 arms, respectively, and 12.9 months (95% CI,
2.8 months to NE), 10.8 months (95% CI, 4.6 months to
NE), and 24.1 months (95% CI, 10.2 months to NE) in
patients with PD-L1 expression of 1% or greater (Appendix
Fig A5, online only).
Any-grade treatment-related AEs (TRAEs) occurred in 66
(84.6%), 88 (84.6%), and 74 patients (80.4%) in the
NIVO3, NIVO3+IPI1, and NIVO1+IPI3 arms, respectively
(Table 3). Grade 3 to 4 TRAEs occurred in 21 (26.9%),
32 (30.8%), and 36 patients (39.1%) in the NIVO3,
NIVO3+IPI1, and NIVO1+IPI3 arms. Grade 5 treatment-
related pneumonitis occurred in one patient each in the
NIVO3 and NIVO3+IPI1 arms. No grade 5 TRAEs occurred
in the NIVO1+IPI3 arm. Any-grade treatment-related se-
rious AEs occurred in nine (11.5%), 26 (25.0%), and 25
patients (27.2%) in the NIVO3, NIVO3+IPI1, and NIVO1+IPI3
arms, respectively, whereas grade 3 to 4 treatment-related
serious AEs occurred in six (7.7%), 21 (20.2%), and
20 patients (21.7%). In the NIVO3 arm, three patients
(3.8%) discontinued treatment as a result of grade 3 or
greater TRAEs. In the NIVO3+IPI1 and NIVO1+IPI3 arms,
12 (11.5%) and 10 patients (10.9%), respectively, dis-
continued treatment because of grade 3 or greater TRAEs.
Treatment-related select AEs included endocrine, GI,
hepatic, pulmonary, renal, and skin events (Table 3).
TABLE 1. Baseline Demographic and Clinical Characteristics
Characteristic
NIVO3
(n = 78)
NIVO3+IPI1
(n = 104)
NIVO1+IPI3
(n = 92)
Median age (range), years 65.5 (31-85) 63.0 (39-83) 64.0 (38-83)
Age, years, No (%)
$ 65 41 (52.6) 47 (45.2) 45 (48.9)
$ 75 10 (12.8) 18 (17.3) 11 (12.0)
Male, No. (%) 54 (69.2) 81 (77.9) 74 (80.4)
Region, No. (%)
United States 59 (75.6) 74 (71.2) 31 (33.7)
Rest of the world 19 (24.4) 30 (28.8) 61 (66.3)
Race, No. (%)
White 72 (92.3) 90 (86.5) 87 (94.6)
Black or African American 4 (5.1) 4 (3.8) 3 (3.3)
Asian 1 (1.3) 4 (3.8) 1 (1.1)
Other 1 (1.3) 6 (5.8) 1 (1.1)
ECOG PS, No (%)
0 42 (53.8) 40 (38.5) 41 (44.6)
1 36 (46.2) 64 (61.5) 51 (55.4)
Baseline liver metastasis, No. (%) 20 (25.6) 37 (35.6) 33 (35.9)
Baseline visceral metastasis, No. (%) 64 (82.1) 92 (88.5) 76 (82.6)
Baseline lymph node only metastasis,
No. (%)
13 (16.7) 11 (10.6) 15 (16.3)
Baseline creatinine
clearance,mL/min,
No. (%)
, 60 25 (32.1) 36 (34.6) 26 (28.3)
$ 60 53 (67.9) 68 (65.4) 66 (71.7)
Percent tumor PD-L1 expression, No.
(%)
, 1 43 (55.1) 56 (53.8) 42 (45.7)
$ 1 26 (33.3) 31 (29.8) 31 (33.7)
Not quantifiable 9 (11.5) 17 (16.3) 19 (20.7)
No. of Bellmunt risk factors, No. (%)
0 27 (34.6) 26 (25.0) 29 (31.5)
1 39 (50.0) 42 (40.4) 35 (38.0)
$ 2 12 (15.4) 36 (34.6) 28 (30.4)
No. of prior regimens,
No. (%)
0 0 2 (1.9) 3 (3.3)
1 27 (34.6) 36 (34.6) 29 (31.5)
$ 2 51 (65.4) 66 (63.5) 60 (65.2)
Abbreviations: ECOGPS, Eastern Cooperative OncologyGroupperformance status;
NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab
3mg/kg plus ipilimumab 1mg/kg every 3 weeks for four doses followed by nivolumab
monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus
ipilimumab 3mg/kg every 3 weeks for four doses followed by nivolumabmonotherapy
3 mg/kg every 2 weeks; PD-L1, programmed death ligand 1.
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Anygrade treatment-related select AEs that occurred in
10% or more of patients were endocrine (n = 9; 11.5%),
GI (n = 11; 14.1%), and skin (n = 34; 43.6%) in the
NIVO3 arm; endocrine (n = 24; 23.1%), GI (n = 26;
25.0%), hepatic (n = 29; 27.9%), and skin (n = 44;
42.3%) in the NIVO3+IPI1 arm; and endocrine (n = 22;
23.9%), GI (n = 32; 34.8%), hepatic (n = 15; 16.3%), and
skin (n = 42; 45.7%) in the NIVO1+IPI3 arm (Table 3).
Most patients received immune-modulating medication
for grade 3 to 4 treatment-related select AEs (Appendix
Table A2, online only). In all arms, the majority of grade 3
to 4 treatment-related select AEs resolved when immune-
modulating medication was initiated (Appendix Table A2).
DISCUSSION
In CheckMate 032, NIVO3 continues to provide antitumor
benefit with durable responses and prolonged OS with
longer follow-up. Our results show evidence of clinical
activity with combined PD-1 and cytotoxic T-lymphocyte
Enrolled (N = 345)
 Not assigned    (n = 65)
   No longer met study criteria    (n = 53)
   Withdrew consent      (n = 8)
   AE      (n = 2)
   Died      (n = 2)
Analyzed for efficacy (n = 78)
Analyzed for safety (n = 78)
Analyzed for efficacy (n = 104)
Analyzed for safety (n = 104)
Analyzed for efficacy (n = 92)
Analyzed for safety (n = 92)
Discontinued (n = 71)
  Disease progressed (n = 56)
  Study drug toxicity   (n = 3)
  AE unrelated to study drug   (n = 6)
  Patient request   (n = 3)
  Withdrew consent   (n = 1)
  Maximum clinical benefit   (n = 1)
  Poor/noncompliance   (n = 1)
Discontinued  (n = 96)
  Disease progressed  (n = 71)
  Study drug toxicity  (n = 15)
  AE unrelated to study drug    (n = 5)
  Patient request    (n = 1)
  Withdrew consent    (n = 1)
  Poor/noncompliance    (n = 1)
  Other    (n = 2)
Discontinued (n = 70)
  Disease progressed (n = 50)
  Study drug toxicity (n = 12)
  AE unrelated to study drug   (n = 3)
  Patient request   (n = 1)
  Withdrew consent   (n = 1)
  Maximum clinical benefit   (n = 1)
  Other   (n = 2)
Assigned to NIVO3 (n = 82)
Received NIVO3 (n = 78)
Did not receive NIVO3   (n = 4)
  No longer met study treatment   (n = 3)
  Withdrew consent   (n = 1)
Assigned to NIVO3+IPI1 (n = 106)
Received NIVO3+IPI1 (n = 104)
Did not receive NIVO3+IPI1     (n = 2)
  No longer met study criteria     (n = 2)
Assigned to NIVO1+IPI3 (n = 92)
Received NIVO1+IPI3 (n = 92)
FIG 1. CONSORT diagram. AE, adverse event; NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus
ipilimumab 1mg/kg every 3 weeks for four doses followed by nivolumabmonotherapy 3mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1mg/kg
plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
TABLE 2. Best Overall Response Per Investigator and Per BICR
Response
Per Investigator Per BICR
NIVO3 (n = 78)
NIVO3+IPI1
(n = 104)
NIVO1+IPI3
(n = 92) NIVO3 (n = 78)
NIVO1+IPI3
(n = 92)
ORR, No. (%) 20 (25.6) 28 (26.9) 35 (38.0) 16 (20.5) 34 (37.0)
95% CI 16.4 to 36.8 18.7 to 36.5 28.1 to 48.8 12.2 to 31.2 27.1 to 47.7
Best overall response, No. (%)
Complete response 8 (10.3) 8 (7.7) 6 (6.5) 9 (11.5) 14 (15.2)
Partial response 12 (15.4) 20 (19.2) 29 (31.5) 7 (9.0) 20 (21.7)
Stable disease 21 (26.9) 24 (23.1) 23 (25.0) 27 (34.6) 24 (26.1)
Progressive disease 30 (38.5) 44 (42.3) 20 (21.7) 31 (39.7) 21 (22.8)
Unable to determine/not reported 7 (9.0) 8 (7.7) 14 (15.2) 4 (5.1) 13 (14.1)
Abbreviations: BICR, blinded independent central review; NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus
ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus
ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; ORR, objective response rate.
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antigen-4 inhibition in mUC, as previously observed with
nivolumab plus ipilimumab across several tumor types.11-14
Especially promising efficacy was observed with the
NIVO1+IPI3 combination, which resulted in the highest
ORRs relative to the NIVO3 and NIVO3+IPI1 arms, although
the study design precludes direct comparison. Furthermore,
ORR with the NIVO1+IPI3 combination is higher than has
been previously reported with other currently approved
anti–PD-1 and anti–PD-L1monotherapy agents, although this
should be interpreted with caution.4-8 The promising efficacy
observed with theNIVO1+IPI3 combination was also reflected
in the prolonged OS and the greater proportion of patients with
increased reduction in target lesions from baseline relative to
the NIVO3 and NIVO3+IPI1 arms. However, additional follow-
up will help fully characterize the clinical activity of the
NIVO1+IPI3 combination regimen.
Responses were observed regardless of PD-L1 expression
levels in all treatment arms. In this initial analysis of the
NIVO1+IPI3 expansion cohort, ORR was highest in patients
with baseline tumor PD-L1 expression of 1% or greater.
This finding was consistent with ORR as assessed by BICR.
Responses per investigator or per BICR in patients with
baseline tumor PD-L1 expression less than 1%were similar
across regimens; however, analysis of ORR by PD-L1 ex-
pression levels was exploratory and limited by the small
numbers of patients in these subgroups.
The ORR, per investigator, was 38.0% (37.0% by BICR)
with NIVO1+IPI3. In previous reports of PD-1– and PD-
L1–targeted monotherapies, including pembrolizumab,
nivolumab, atezolizumab, avelumab, and durvalumab, in
a PD-L1–unselected population of patients with mUC, ORR
ranged from 13.4% to 21.1%.4-8 Previously, the highest
ORR reportedwith immunotherapy in the platinum-pretreated
population was 21.1% at median follow-up of 27.7 months in
the KEYNOTE-045 trial of pembrolizumab versus in-
vestigator’s choice of chemotherapy.4
Median OS of 15.3 months and the 1-year OS rate in this
study of 56.9% were also promising. In studies of other
immune checkpoint inhibitor monotherapies in this setting,
median OS ranged from 6.5 to 10.5 months and 1-year
OS rate ranged from 39% to 55%.4-9 Durable responses
with nivolumab plus ipilimumab treatments have been
observed in patients with melanoma and RCC.11,14
Longer follow-up with NIVO1+IPI3 in patients with
mUC will indicate whether durability of response holds
true in this malignancy.
In CheckMate 032, patients in the mUC cohort were heavily
pretreated. The proportion of patients who received two or
more prior regimens (65.2%) was greater than that re-
ported in several other trials of immunotherapy agents in
the previously treated mUC setting.5,6,21 The results in this
heavily pretreated population are encouraging as it is
known that these patients have limited subsequent
treatment options. Patients also had a high rate of vis-
ceral metastases at baseline, which is associated with
poor prognosis.22 In addition, more than one third of
patients had baseline liver metastases and approxi-
mately one third of patients had two or more Bellmunt
risk factors in both combination arms, which further
highlights the notable efficacy of NIVO1+IPI3, even in
patients with poor prognoses and high unmet need.
The safety profiles of the three nivolumab-containing
regimens were similar and consistent with the previously
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FIG 2. Best tumor change from baseline in target lesion per in-
vestigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks;
NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every
3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg
every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab
3 mg/kg every 3 weeks for four doses followed by nivolumab mono-
therapy 3 mg/kg every 2 weeks.
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reported safety profile of nivolumab monotherapy in
CheckMate 032,16 and the incidence of certain AEs
was consistent with the safety profiles of nivolumab plus ipili-
mumab in other cancer types.11,14 However, the incidence of
high-grade TRAEs or high-grade treatment-related select AEs
and the use of immune-modulating medication for high-grade
treatment-related select AE resolution was highest in the
NIVO1+IPI3 arm and may have arisen because of ipilimumab
dose-related toxicity. Grade 3 to 4 treatment-related select AEs
largely resolved with the use of immune-modulating medica-
tion. No new safety signals were observed with NIVO1+IPI3 in
patients with mUC, and the incidence of both any-grade TRAEs
andgrade3or greater TRAEswas lower thanhasbeen reported in
patientswith unresectable stage III or IVmelanoma.11 Similarly, the
safety profile of NIVO3+IPI1 in the current study was consistent
with that in patients with previously untreated advanced RCC
who received the same dosing schedule of the NIVO plus IPI
combination.14
This study is limited by the fact that it was not designed to
directly compare outcomes among treatment arms, which
each have a different length of follow-up, or with a stan-
dard current practice comparator. However, the ongoing
phase III CheckMate 901 trial will further evaluate the
NIVO1+IPI3 combination versus chemotherapy in pa-
tients with previously untreated mUC (ClinicalTrials.gov
identifier: NCT03036098). The relatively small sample
size in each arm of the current study could also be
a limitation, especially in evaluating the effects of tumor
PD-L1 expression on efficacy. Longer-term follow-up is
needed to further characterize the efficacy and safety of
the NIVO1+IPI3 combination.
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In summary, these results show the continued clinical
benefit with NIVO3 monotherapy and highlight the
especially promising efficacy of NIVO1+IPI3 combi-
nation therapy in patients with platinum-pretreated
locally advanced or mUC from CheckMate 032. The
safety profile of this combination was manageable and
similar to that of the NIVO3 and NIVO3+IPI1 regimens.
These results provide a strong rationale by which
to evaluate NIVO1+IPI3 in the first-line setting for
mUC.
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TABLE 3. Treatment-Related Adverse Events in 10% or More of Patients and Treatment-Related Select Adverse Events
Adverse Event
NIVO3 (n = 78) NIVO3+IPI1 (n = 104) NIVO1+IPI3 (n = 92)
Any Grade Grade 3 to 4 Any Grade Grade 3 to 4 Any Grade Grade 3 to 4
Treatment-related adverse event 66 (84.6) 21 (26.9)* 88 (84.6) 32 (30.8)* 74 (80.4) 36 (39.1)
Diarrhea 10 (12.8) 0 24 (23.1) 5 (4.8) 30 (32.6) 9 (9.8)
Pruritus 26 (33.3) 0 30 (28.8) 2 (1.9) 29 (31.5) 0
Fatigue 28 (35.9) 2 (2.6) 33 (31.7) 3 (2.9) 24 (26.1) 0
Decreased appetite 6 (7.7) 0 17 (16.3) 0 15 (16.3) 0
Maculopapular rash 17 (21.8) 3 (3.8) 19 (18.3) 2 (1.9) 15 (16.3) 3 (3.3)
Nausea 10 (12.8) 1 (1.3) 8 (7.7) 1 (1.0) 13 (14.1) 1 (1.1)
Hypothyroidism 6 (7.7) 0 14 (13.5) 0 12 (13.0) 0
Rash 6 (7.7) 0 13 (12.5) 2 (1.9) 12 (13.0) 1 (1.1)
Elevated ALT 3 (3.8) 0 20 (19.2) 6 (5.8) 12 (13.0) 6 (6.5)
Elevated AST 1 (1.3) 1 (1.3) 16 (15.4) 4 (3.8) 10 (10.9) 2 (2.2)
Lipase increased 13 (16.7) 5 (6.4) 10 (9.6) 6 (5.8) 5 (5.4) 4 (4.3)
Arthralgia 12 (15.4) 0 9 (8.7) 0 6 (6.5) 0
Anemia 9 (11.5) 1 (1.3) 12 (11.5) 1 (1.0) 6 (6.5) 0
Dyspnea 8 (10.3) 2 (2.6) 8 (7.7) 1 (1.0) 2 (2.2) 0
Dry skin 8 (10.3) 0 10 (9.6) 0 5 (5.4) 0
Hyperthyroidism 4 (5.1) 0 13 (12.5) 0 6 (6.5) 0
Amylase increased 7 (9.0) 4 (5.1) 11 (10.6) 1 (1.0) 6 (6.5) 2 (2.2)
Select adverse event
Endocrine 9 (11.5) 0 24 (23.1) 3 (2.9) 22 (23.9) 2 (2.2)
GI 11 (14.1) 1 (1.3) 26 (25.0) 8 (7.7) 32 (34.8) 15 (16.3)
Hepatic 6 (7.7) 2 (2.6) 29 (27.9) 7 (6.7) 15 (16.3) 9 (9.8)
Pulmonary* 2 (2.6) 0 7 (6.7) 1 (1.0) 5 (5.4) 2 (2.2)
Renal 7 (9.0) 2 (2.6) 7 (6.7) 0 3 (3.3) 1 (1.1)
Skin 34 (43.6) 3 (3.8) 44 (42.3) 2 (1.9) 42 (45.7) 4 (4.3)
NOTE. Data are presented as No. (%).
Abbreviations: NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every
3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
*Two grade 5 pneumonitis events were reported, one in the NIVO3 group and one in the NIVO3+IPI1 group.
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FIG A1. Objective response rate by tumor programmed death ligand 1 (PD-L1) expression (A) per investigator and
(B) per blinded independent central review. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1,
nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy
3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses
followed by nivolumab monotherapy 3 mg/kg every 2 weeks; ORR, objective response rate.
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FIG A2. Percent reduction from baseline in target lesions per investigator. Horizontal
reference line indicates the 30% reduction consistent with a protocol-defined criteria
response. Assessments are per investigator assessment using protocol-defined criteria.
Crossover patients are truncated at the crossover date. NIVO3, nivolumab 3 mg/kg
monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3mg/kg plus ipilimumab 1mg/kg
every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every
2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for
four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
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FIG A3. Time to and duration of response per investigator. NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1, nivolumab 3 mg/kg plus
ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus
ipilimumab 3 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
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FIG A4. Progression-free survival (PFS) by tumor programmed death ligand 1 (PD-L1) expression per
investigator. (A) NIVO3 (nivolumab 3 mg/kg monotherapy every 2 weeks). (B) NIVO3+IPI1 (nivolumab
3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy
3mg/kg every 2 weeks). (C) NIVO1+IPI3 (nivolumab 1mg/kg plus ipilimumab 3mg/kg every 3 weeks for
four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks).
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FIG A5. Overall survival (OS) by tumor programmed death ligand 1 (PD-L1) expression. (A) NIVO3
(nivolumab 3 mg/kg monotherapy every 2 weeks). (B) NIVO3+IPI1 (nivolumab 3 mg/kg plus ipilimumab
1 mg/kg every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks).
(C) NIVO1+IPI3 (nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses followed by
nivolumab monotherapy 3 mg/kg every 2 weeks). NE, not estimable.
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List of Study Sites and Investigators
Study Site Principal Investigator
Righospitalet, Copenhagen, Denmark Ulrik Lassen
Helsinki University Hospital, Helsinki, Finland Petri Bono
University of Bonn, Bonn, Germany Peter Brossart
Nationales Centrum Fuer Tumorerkrakungen Heidelberg, Heidelberg, Germany Dirk Jaeger
Azienda Ospedaliera S Orsola-Malpighi, Bologna, Italy Andrea Ardizzoni
Instituto Nazionale Tumori Fondazione G Pascale, Naples, Italy Paolo A. Ascierto
Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori Milano, Milan, Italy Filippo de Braud
Istituto Oncologico Veneto, Padova, Italy Valentina Guarneri
Hospital Madrid Norte Sanchinarro, Madrid, Spain Emiliano Calvo
University Hospital 12 de Octubre, Madrid, Spain Jose´ Lopez-Martin
Fundacion Jimenez Diaz, Madrid, Spain Victor Moreno Garcia
Hospital Clinic of Barcelona, Barcelona, Spain Noemi Reguart
Royal Marsden Hospital, Sutton, United Kingdom Ian Chau
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom Thomas Ronald Jeffry Evans
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL Scott Antonia
Levine Cancer Institute, Charlotte, NC Asim Amin
Tennessee Oncology, Nashville, TN Johanna Bendell
Vanderbilt-Ingram Cancer Center, Nashville, TN David Chism
Yale University, New Haven, CT Joseph Eder
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD Dung T. Le
Duke Cancer Institute, Durham, NC Michael Morse
Dana-Farber Cancer Institute, Boston, MA Patrick A. Ott
Winship Cancer Institute, Atlanta, GA Rathi N. Pillai
Memorial Sloan Kettering Cancer Center, New York, NY Margaret Callahan
The University of Texas MD Anderson Cancer Center, Houston, TX Padmanee Sharma
Oregon Health and Science University, Portland, OR Matthew Taylor
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TABLE A1. Best Overall Response and Duration of Response by Tumor PD-L1 Expression per Investigator
Response
NIVO3 NIVO3+IPI1 NIVO1+IPI3
PD-L1 < 1%
(n = 43)
PD-L1 ‡ 1%
(n = 26)
PD-L1 < 1%
(n = 56)
PD-L1 ‡ 1%
(n = 31)
PD-L1 < 1%
(n = 42)
PD-L1 ‡ 1%
(n = 31)
ORR, No. (%) 11 (25.6) 7 (26.9) 14 (25.0) 11 (35.5) 10 (23.8) 18 (58.1)
95% CI 13.5 to 41.2 11.6 to 47.8 14.4 to 38.4 19.2 to 54.6 12.1 to 39.5 39.1 to 75.5
Best overall response, No. (%)
Complete response 5 (11.6) 3 (11.5) 3 (5.4) 3 (9.7) 3 (7.1) 2 (6.5)
Partial response 6 (14.0) 4 (15.4) 11 (19.6) 8 (25.8) 7 (16.7) 16 (51.6)
Stable disease 12 (27.9) 7 (26.9) 11 (25.0) 6 (19.4) 14 (33.3) 5 (16.1)
Progressive disease 18 (41.9) 9 (34.6) 24 (42.9) 13 (41.9) 9 (21.4) 6 (19.4)
Unable to determine/not reported 2 (4.7) 3 (11.5) 4 (7.1) 1 (3.2) 9 (21.4) 2 (6.5)
n = 11 n = 7 n = 14 n = 11 n = 10 n = 18
Median duration of response, months 40.8 19.4 21.5 NR 21.4 22.9
95% CI 5.6 to NE 8.3 to 37.1 7.1 to NE 6.7 to NE 1.8 to NE 8.6 to 26.5
Abbreviations: NE, not estimable; NIVO3, nivolumab3mg/kgmonotherapy every 2weeks; NIVO3+IPI1 nivolumab 3mg/kg plus ipilimumab1mg/kg every 3weeks
for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI3, nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses
followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NR, not reached; ORR, objective response rate; PD-L1, programmed death ligand 1.
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TABLE A2. Time to Onset and Resolution of Grade 3 to 5 Treatment-Related Select Adverse Events for Which Immune-Modulating Medication
Was Initiated, by Category
Variable NIVO3 NIVO3+IPI1 NIVO1+IPI3
Median time to onset of grade 3-5 treatment-related select adverse
events, weeks (range)
Endocrine n = 0 n = 3 n = 2
— 15.7 (11.7-24.7) 9.8 (8.9-10.7)
GI n = 1 n = 8 n = 15
4.9 (4.9-4.9) 7.4 (0.3-20.7) 7.9 (1.6-53.1)
Hepatic n = 2 n = 7 n = 9
35.1 (6.1-64.1) 11.3 (3.0-96.0) 9.1 (4.6-42.7)
Pulmonary n = 1 n = 2 n = 2
4.4 (4.4-4.4) 6.0 (3.9-8.1) 3.9 (2.6-5.3)
Renal n = 2 n = 0 n = 1
84.6 (31.1-138.1) — 9.0 (9.0-9.0)
Skin n = 3 n = 2 n = 4
7.9 (1.1-54.3) 43.6 (19.7-67.6) 3.8 (2.1-6.0)
No. of patients receiving immune-modulating medication for grade 3 to 4
treatment-related select adverse events, No. (%)
Endocrine 0 1 (33.3) 2 (100.0)
GI 1 (100.0) 7 (87.5) 14 (93.3)
Hepatic 2 (100.0) 5 (71.4) 6 (66.7)
Pulmonary 1 (100.0) 1 (50.0) 2 (100.0)
Renal 1 (50.0) 0 1 (100.0)
Skin 2 (66.7) 2 (100.0) 4 (100.0)
No. of patients whose grade 3 to 4 treatment-related select adverse events
resolved when immune-modulating medication was initiated,
No. (%)
Endocrine n = 0 n = 3 n = 2
— 1 (33.3) 0 (0)
GI n = 1 n = 7 n = 15
1 (100.0) 6 (85.7) 14 (93.3)
Hepatic n = 2 n = 6 n = 7
1 (50.0) 6 (100.0) 5 (71.4)
Pulmonary n = 1 n = 1 n = 2
0 (0) 0 (0) 2 (100.0)
Renal n = 1 n = 0 n = 1
1 (100.0) — 1 (100.0)
Skin n = 2 n = 2 n = 4
2 (100.0) 1 (50.0) 4 (100.0)
Abbreviations: NIVO3, nivolumab 3 mg/kg monotherapy every 2 weeks; NIVO3+IPI1 nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every
3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks; NIVO1+IPI nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
every 3 weeks for four doses followed by nivolumab monotherapy 3 mg/kg every 2 weeks.
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